Internet-delivered Acceptance and Commitment Therapy for Patients With Health Anxiety

April 27, 2021 updated by: University of Aarhus

Internet-delivered Acceptance and Commitment Therapy for Patients With Health Anxiety: a Randomized Controlled Trial

Health anxiety is a prevalent, disabling disorder associated with extensive health care expenditures. The lack of easily accessible, evidence-based psychological treatment combined with delayed diagnostic recognition constitute barriers to receiving treatment.

Aim

  1. To develop an internet-delivered treatment program, based on 'Acceptance and Commitment Therapy' (ACT), for patients with health anxiety.
  2. To test the feasibility and effectiveness of the treatment programme in a randomized, controlled trial, comparing the treatment with an active control condition.

Methods 150 patients aged 18 years and older can self-refer through a web-page to apply for participation. Before inclusion patients will undergo a video-diagnostic interview. Patients are randomly assigned to 12 weeks of either, 1) active treatment: consisting of internet-based ACT (iACT) with 7 therapist-guided modules of self-help text, exercises, patient videos and audio-files, or 2) active control condition: consisting of an internet-based discussion forum (iFORUM) with 7 topics of discussion.

All patients will complete self-report questionnaires at baseline, before randomization, at 4 and 8 weeks into treatment, after end of treatment, and at 6-month follow-up.

Study Overview

Detailed Description

Severe health anxiety (illness anxiety disorder) or hypochondriasis, according to the psychiatric classification system ICD-10, is characterized by preoccupation with fear of having a serious illness, which interferes with daily functions and persists despite medical reassurance. Clinical significant health anxiety is prevalent in primary care with 0.8-9.5%, and has a lifetime prevalence of 5.7% in the general population. It is a disabling disorder, associated with extensive use of health care services and occupational disability.

Earlier, health anxiety has been considered a chronic disease with poor treatment outcomes. A recent review found effect of both medicine and psychotherapy, but patients may prefer psychotherapeutic treatments. Despite the high prevalence, health anxiety is rarely diagnosed within primary care, and there is limited access to evidence-based treatment for health anxiety.

An easily accessible, evidence-based treatment is needed for this debilitating condition.

Internet-based treatment is a new approach where patients receive access to a guided self-help program. A meta-analysis has shown equal treatment effects of internet-based treatment compared to "face-to-face" treatment for depressive- and anxiety disorders. Internet-based cognitive behavioral therapy for health anxiety has shown to be cost-effective. ACT is a new effective generation of cognitive-behavioral therapy, with an emphasis on acceptance and value-based exposure that has shown good results for treating health anxiety in a group setting. Internet-based Cognitive behavioral therapy (CBT) for health anxiety has shown promising results but low treatment completion. This may be due to the comprehensive treatment modules and the text-based format. ACT is an experiential behavioral therapy, and aims to activate patients with exercises, videos, audio-files and less text material.

Most persons with health anxiety have high health care expenditure. However, some patients with health anxiety avoid contact to the health care system, and may not receive proper treatment. Patient self-referral is a new approach that may facilitate access to treatment.

Aim

  1. To develop an internet-delivered treatment program for patients suffering from health anxiety based on ACT.
  2. To test the feasibility and effectiveness of the treatment programme in a randomized, controlled trial, comparing treatment with an active control condition.

Hypothesis Primary hypothesis Patients with health anxiety treated with iACT will at 6-month follow-up report a significant reduction in illness worry compared to the action control condition iFORUM.

Secondary hypotheses

Patients with health anxiety treated with iACT compared to the active control condition iFORUM will at 6-month follow-up report:

  1. a reduction in physical symptoms and symptoms of anxiety and depression
  2. increased health-related quality of life
  3. more expedient illness perceptions and increased acceptance of symptoms

    Mediation analyses

  4. changes in illness perception and acceptance mediate the effect of iACT

Study Type

Interventional

Enrollment (Actual)

101

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Severe health anxiety > 6 months
  2. Whiteley-7 score (scale 0-100 score points) corresponding to 21,4 or more.
  3. Age above 18 years old
  4. In case of a comorbid functional or other psychiatric disorder health anxiety must be the dominant problem
  5. Patients who speak, read and write Danish
  6. Access to a computer and internet access
  7. Residence in Denmark

Exclusion criteria:

  1. Acute suicidal risk
  2. Abuse of narcotics or alcohol and (non-prescribed) medicine
  3. Lifetime-diagnosis of psychoses, bipolar affective disorder or depression with psychotic symptoms (ICD-10: F20-29, F30-31, F32.3, F33.3)
  4. Pregnancy
  5. Unstable psychopharmacological treatment within last 2 months
  6. Former treatment at the Research Clinic for Functional Disorders and Psychosomatics
  7. Not providing informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Internet-based ACT
Brief clinical psychiatric assessment to determine eligibility (video-based).
The guided internet program consists of 7 modules activated consecutively over a period of 12 weeks. The content is written psycho education, patient videos, audio-exercises and behavioural exposure exercises. The program is therapist-guided; hence all patients will receive support from primarily the same therapist during the 12 weeks.
ACTIVE_COMPARATOR: Internet-based discussion forum
Brief clinical psychiatric assessment to determine eligibility (video-based).
The online discussion forum consists of 7 themes touching upon the impact of health anxiety and the patients own coping strategies. The themes are activated consecutively over a period of 12 weeks. The discussion forum is text-based, and only patients will participate in the discussion. The written discussions will be reviewed by a professional for ethical reasons. The discussion forum aims to control for the effect of attention and contacts to the health care system. After 9 months patients in the discussion forum are offered active treatment, but not as part of the research project.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Whiteley-7 index
Time Frame: At baseline (i.e. at self-referral), before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline) and 1, 2, 3 and 9 months after randomisation
Health anxiety symptoms
At baseline (i.e. at self-referral), before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline) and 1, 2, 3 and 9 months after randomisation

Secondary Outcome Measures

Outcome Measure
Time Frame
Demographic questions measured with questions from the Danish study for Functional Disorders (DanFund)
Time Frame: At baseline (i.e. at self-referral)
At baseline (i.e. at self-referral)
Diagnosed somatic illnesses measured with questions from the Danish study for Functional Disorders (DanFund)
Time Frame: At baseline (i.e. at self-referral)
At baseline (i.e. at self-referral)
Quality of life measured with the World Health Organisation Well-being Index-Five (WHO-5)
Time Frame: At baseline (i.e. at self-referral), before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline) and 1, 2, 3 and 9 months after randomisation
At baseline (i.e. at self-referral), before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline) and 1, 2, 3 and 9 months after randomisation
Quality of life measured with the visual analogue scale (VAS question) from Youth profile, National Institute of Public Health
Time Frame: At baseline (i.e. at self-referral), before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline) and 1, 2, 3 and 9 months after randomisation
At baseline (i.e. at self-referral), before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline) and 1, 2, 3 and 9 months after randomisation
Stress measured with questions from the survey Youth stress, Danish Health Authority
Time Frame: At baseline (i.e. at self-referral), before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline) and 1, 2, 3 and 9 months after randomisation
At baseline (i.e. at self-referral), before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline) and 1, 2, 3 and 9 months after randomisation
Health anxiety symptoms measured with the Short Health Anxiety Inventory (SHAI)
Time Frame: At baseline (i.e. at self-referral), and 3 and 9 months after randomisation
At baseline (i.e. at self-referral), and 3 and 9 months after randomisation
Anxiety, depression, obsessive-compulsive and physical symptoms measured with subscales from the Symptom Checklist (SCL-92)
Time Frame: At baseline (i.e. at self-referral), and 3 and 9 months after randomisation
At baseline (i.e. at self-referral), and 3 and 9 months after randomisation
Somatisation measured with the Bodily Distress Syndrome Checklist (BDS Checklist)
Time Frame: At baseline (i.e. at self-referral)
At baseline (i.e. at self-referral)
General health status and functioning measured with the Short Form 12 Health Survey (SF-12)
Time Frame: At baseline (i.e. at self-referral), before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline), 3 and 9 months after randomisation
At baseline (i.e. at self-referral), before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline), 3 and 9 months after randomisation

Other Outcome Measures

Outcome Measure
Time Frame
Psychological flexibility measured with the Acceptance and Action Questionnaire-II (AAQ-II)
Time Frame: At baseline (i.e. at self-referral), and 1, 2, 3 and 9 months after randomisation
At baseline (i.e. at self-referral), and 1, 2, 3 and 9 months after randomisation
Non-reactivity measured with a subscale of the Five Facet Mindfulness Questionnaire (FFMQ)
Time Frame: At baseline (i.e. at self-referral), and 1, 2, 3 and 9 months after randomisation
At baseline (i.e. at self-referral), and 1, 2, 3 and 9 months after randomisation
Illness perception measured with the Brief Illness Perception Questionnaire (B-IPQ)
Time Frame: At baseline (i.e. at self-referral), and 1, 2, 3 and 9 months after randomisation
At baseline (i.e. at self-referral), and 1, 2, 3 and 9 months after randomisation
Personality traits measured with the short version of the Big Five Inventory (BFI-10)
Time Frame: Before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline)
Before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline)
Working alliance measured with the Working Alliance Inventory, Patient version (WAI-pt)
Time Frame: 2 weeks into treatment, and 3 months after randomisation
2 weeks into treatment, and 3 months after randomisation
Treatment credibility and expectancy measured with the credibility/ expectancy questionnaire
Time Frame: Before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline)
Before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline)
Childhood history questionnaire
Time Frame: Before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline)
Before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline)
Traumatic events in childhood measured with the Childhood traumatic event scale
Time Frame: Before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline)
Before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline)
Attachment style measured with the questionnaire: Experiences in close relationships - relationship structures (ECR-RS)
Time Frame: Before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline)
Before randomisation (i.e. after clinical assessment and up to 6 weeks after baseline)
Treatment evaluation of negative effects measured with the Inventory for the assessment of negative effects of psychotherapy (INEP)
Time Frame: 9 months after randomisation
9 months after randomisation
Attitudes toward seeking professional help
Time Frame: At baseline (i.e. at self-referral) and at 3 months after randomisation
At baseline (i.e. at self-referral) and at 3 months after randomisation
Self-reported health care use, work performance and work absence measured with Trimbos/ institute of Health Policy and Management (iMTA) questionnaire for Costs associated with Psychiatric Illness (TiC-P)
Time Frame: At baseline (i.e. at self-referral) and at 9 months after randomisation
At baseline (i.e. at self-referral) and at 9 months after randomisation
Health care expenditures extracted from Danish national registers, and degree of illness related absence from work extracted from the Danish Register of Sickness absence compensation benefits and Social transfer payments database (DREAM).
Time Frame: At baseline (i.e. at self-referral) and at 9 months after randomisation
At baseline (i.e. at self-referral) and at 9 months after randomisation
Health literacy measured with the Health Literacy Questionnaire (HLQ)
Time Frame: At baseline (i.e. at self-referral)
At baseline (i.e. at self-referral)
Values measured with the Sources of Meaning and Meaning in life questionnaire (SoMe-26)
Time Frame: At baseline (i.e. at self-referral), and 1, 2, 3 and 9 months after randomisation
At baseline (i.e. at self-referral), and 1, 2, 3 and 9 months after randomisation
Negative events and effects of psychological treatment
Time Frame: At 3 months after randomisation
At 3 months after randomisation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Charlotte U Rask, PhD, Aarhus University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

April 1, 2016

Primary Completion (ACTUAL)

April 1, 2017

Study Completion (ACTUAL)

March 1, 2018

Study Registration Dates

First Submitted

April 1, 2016

First Submitted That Met QC Criteria

April 11, 2016

First Posted (ESTIMATE)

April 12, 2016

Study Record Updates

Last Update Posted (ACTUAL)

April 30, 2021

Last Update Submitted That Met QC Criteria

April 27, 2021

Last Verified

March 1, 2017

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 09032016

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypochondriasis

Clinical Trials on Internet-based ACT

3
Subscribe